Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma:A Phase II, Prospective, Multicenter, Single-Arm Clinical Study

NCT07355699 is registered in ClinicalTrials.gov with Beijing Tongren Hospital as lead sponsor.

NCT NCT07355699
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07355699 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma:A Phase II, Prospective, Multicenter, Single-Arm Clinical Study
Lead sponsor
Beijing Tongren Hospital
Phase
Phase 4
Overall status
Recruiting
Start date
November 25, 2025
Completion date
December 31, 2028
Enrollment
88 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

marginal zone lymphoma(mzl)